# A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

> **NCT07082920** · PHASE1 · RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 140 (estimated)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** JNJ-78278343
- **DRUG:** JNJ-95298177

## Key facts

- **NCT ID:** NCT07082920
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-07
- **Primary completion:** 2027-01-28
- **Final completion:** 2027-03-01
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07082920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07082920, "A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07082920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*